OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Ornstein on Challenges With Immunotherapy in RCC

August 17th 2017

Moshe Ornstein, MD, staff, Cleveland Clinic, discusses the challenges surrounding immunotherapy for patients with renal cell carcinoma.

Dr. Byrd on Long-term Safety Data With Ibrutinib in CLL

August 17th 2017

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses long-term safety data with ibrutinib (Imbruvica) as treatment for patients with chronic lymphocytic leukemia (CLL).

Dr. Slovin on Approaches of Immunotherapy in Prostate Cancer

August 17th 2017

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses approaches of immunotherapy for patients with prostate cancer.

Dr. Brawer on the Significance of the Prolaris Genetic Test for Prostate

August 17th 2017

Michael Brawer, MD, vice president of medical affairs, Myriad Genetic Laboratories, discusses the significance of the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.

Dr. Wilson on Choosing Between BRAF/MEK Therapies for Patients With Melanoma

August 16th 2017

Melissa A. Wilson, MD, PhD, an assistant professor of medicine at Perlmutter Cancer Center at NYU Langone Medical Center, discusses how physicians select between the 2 BRAF/MEK inhibitor combination regimens for their patients with melanoma.

Dr. Nowakowski on Biological Heterogeneity in Newly Diagnosed Patients With MCL

August 16th 2017

Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses the desire to use biological heterogeneity as a factor for treatment in newly diagnosed patients with mantle cell lymphoma (MCL).

Dr. Chavez Shares His Advice for Treating Patients With CLL

August 16th 2017

Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, shares his advice for oncologists treating patients with chronic lymphocytic leukemia.

Dr. Leath Discusses Surgical Cytoreduction in Ovarian Cancer

August 16th 2017

Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses surgical cytoreduction in ovarian cancer.

Dr. Choyke Discusses Screening in Prostate Cancer

August 16th 2017

Peter Choyke, MD, FACR, chief of the Molecular Imaging Program, National Cancer Institute, discusses screening in prostate cancer.

Dr. Atkins Discusses Response to Atezolizumab in RCC

August 16th 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses responses with atezolizumab (Tecentriq) in renal cell carcinoma.

Dr. Furman on Considering Factors for Upfront Therapy in CLL

August 15th 2017

Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses factors to consider when choosing upfront therapy for patients with chronic lymphocytic leukemia (CLL).

Dr. Annunziata on Efforts to Prevent Gynecologic Cancers

August 15th 2017

Christina M. Annunziata, MD, PhD, investigator, Women's Malignancies Branch, head, Translational Genomics Section, National Cancer Institute, discusses the importance on efforts being done to prevent gynecologic cancers.

Dr. Plimack on the Challenges With Available Immunotherapies for Bladder Cancer

August 15th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, shares the challenges with the FDA-approved immunotherapy agents for the treatment of patients with bladder cancer.

Dr. Ansell on Difficult Challenges in the MCL Landscape

August 15th 2017

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses difficult challenges to overcome in the landscape of mantle cell lymphoma (MCL).

Dr. Choyke on Developments for the Screening of Prostate Cancer

August 15th 2017

Peter Choyke, MD, FACR, chief of Molecular Imagine Program, National Cancer Institute, discusses developments being made in screening for patients with prostate cancer.

Dr. Vokes on Pembrolizumab Plus Chemotherapy and Radiation in Lung Cancer

August 15th 2017

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses pembrolizumab (Keytruda) plus chemotherapy and radiation therapy in patients with lung cancer.

Dr. Weiss Discusses Prevention in Head and Neck Cancer

August 14th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses prevention in head and neck cancer.

Dr. Chavez Discusses Ibrutinib Plus Venetoclax in CLL

August 14th 2017

Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses ibrutinib (Imbruvica) plus venetoclax (Venclexta) in chronic lymphocytic leukemia.

Dr. Gupta Discusses the Shifting Landscape of Kidney Cancer

August 11th 2017

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses the shifting landscape of kidney cancer.

Dr. Arend Discusses Biomarkers in Endometrial Cancer

August 11th 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses biomarkers in endometrial cancer.